Recombinant Human NRG1/HRG1 Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Neuregulin-1 (NRG1) belongs to a family of structurally related glycoproteins encoded by four distinct but related genes, Nrg1, Nrg2, Nrg3, and Nrg4. Through alternative splicing or the use of alternative promoters, Nrg1 encodes more than 14 soluble or transmembrane proteins. Type I NRG1 isoforms include Neu Differentiation Factor, Heregulin, and ARIA. These consist of an N-terminal domain, an Ig-like domain, a linker with a Ser/Thr rich region, an EGF-like domain, a transmembrane segment, and a cytoplasmic domain. Type II isoforms such as Glial Growth Factor have a larger N-terminal domain and lack the Ser/Thr rich linker. Type III isoforms such as Sensory and Motor neuron-Derived Factor lack the Ig-like domain but contain a cysteine rich domain (CRD) and a second transmembrane segment (1 - 5). The alpha and beta splice variants of NRG1 differ in their extracellular juxtamembrane regions (3, 6). This recombinant protein corresponds to the extracellular domain (ECD) of the type I alpha isoforms (Accession # Q7RTV8). NRG1 isoforms exhibit distinct expression patterns and functions (7). The EGF-like domain, which is common to all NRG1 isoforms, is required for Neuregulin binding to ErbB3 or ErbB4 receptors (3). ErbB3 or ErbB4 subsequently heterodimerize with ErbB2, resulting in tyrosine phosphorylation and NRG1 induced signaling (1, 2). Soluble growth factors can be released by TACE/ADAM17, BACE, or ADAM19 mediated shedding of the ECD of transmembrane NRG1 (8 - 10). The cytoplasmic region can be cleaved by gamma -secretase, generating a repressor that inhibits the transcription of proapoptotic genes (11). NRG1 regulates multiple nervous system functions including axon guidance, synapse formation and plasticity, glial cell development, and axon myelination (1, 2). In the heart, NRG1 regulates organ morphogenesis and contractility and also plays a cardioprotective role following tissue injury (12). Multiple polymorphisms and aberrant expression of NRG1 isoforms are associated with the development of schizophrenia and many cancers (1, 2, 13).

We have publications tested in 5 confirmed species: Human, Mouse, Bovine, Primate - Cercopithecus Aethiops, Primate - Chlorocebus aethiops (African Green Monkey).

We have publications tested in 2 applications: Bioassay, Cell Culture.

Showing Publications 1 - 10 of 21. Show All 21 Publications. Collapse Publications.

Publications using 5898-NR	Applications	Species
TT Lemmetyine, EW Viitala, L Wartiovaar, T Kaprio, J Hagström, C Haglund, P Katajisto, TC Wang, E Domènech-M, S Ollila Fibroblast-derived EGF ligand Neuregulin-1 induces fetal-like reprogramming of the intestinal epithelium without supporting tumorigenic growth Disease Models & Mechanisms, 2023-04-03;0(0):. 2023-04-03 [PMID: 36912192] (Bioassay, Mouse)	Bioassay	Mouse
TT Dellaqua, RA Vígaro, LCZ Janini, M Dal Canto, MM Renzini, V Lodde, AM Luciano, J Buratini Neuregulin 1 (NRG1) modulates oocyte nuclear maturation during IVM and improves post-IVF embryo development Theriogenology, 2022-11-03;195(0):209-216. 2022-11-03 [PMID: 36368115] (Bioassay, Bovine)	Bioassay	Bovine
MJ Lee, JC Lee, JH Hsieh, MY Lin, IA Shih, HL You, K Wang Cordycepin inhibits the proliferation of malignant peripheral nerve sheath tumor cells through the p53/Sp1/tubulin pathway American journal of cancer research, 2021-04-15;11(4):1247-1266. 2021-04-15 [PMID: 33948356] (Bioassay, Human)	Bioassay	Human
Z Du, BP Brown, S Kim, D Ferguson, DC Pavlick, G Jayakumara, R Benayed, JN Gallant, YK Zhang, Y Yan, M Red-Brewer, SM Ali, AB Schrock, A Zehir, M Ladanyi, AW Smith, J Meiler, CM Lovly Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting Nature Communications, 2021-03-02;12(1):1382. 2021-03-02 [PMID: 33654076] (Bioassay, Primate - Cercopithecus Aethiops)	Bioassay	Primate - Cercopithecus Aethiops
EM Holloway, M Czerwinski, YH Tsai, JH Wu, A Wu, CJ Childs, KD Walton, CW Sweet, Q Yu, I Glass, B Treutlein, JG Camp, JR Spence Mapping Development of the Human Intestinal Niche at Single-Cell Resolution Cell Stem Cell, 2020-12-04;0(0):. 2020-12-04 [PMID: 33278341] (Bioassay, Human)	Bioassay	Human
JS Lee, JY Lee, DW Song, HS Bae, HM Doo, HS Yu, KJ Lee, HK Kim, H Hwang, G Kwak, D Kim, S Kim, YB Hong, JM Lee, BO Choi Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice Nucleic Acids Res., 2020-01-10;0(0):. 2020-01-10 [PMID: 31713617] (Cell Culture, Human)	Cell Culture	Human
TA Ahmed, C Adamopoulo, Z Karoulia, X Wu, R Sachidanan, SA Aaronson, PI Poulikakos SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors Cell Rep, 2019-01-02;26(1):65-78.e5. 2019-01-02 [PMID: 30605687] (Bioassay, Human)	Bioassay	Human
JP Turowec, EWT Lau, X Wang, KR Brown, FA Fellouse, KK Jawanda, J Pan, J Moffat, S Sidhu Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response J. Biol. Chem., 2018-12-06;0(0):. 2018-12-06 [PMID: 30523157] (Bioassay, Human)	Bioassay	Human
T Osada, ZC Hartman, J Wei, G Lei, AC Hobeika, WR Gwin, MA Diniz, N Spector, TM Clay, W Chen, MA Morse, HK Lyerly Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers Breast Cancer Res., 2018-08-09;20(1):90. 2018-08-09 [PMID: 30092835] (Bioassay, Human)	Bioassay	Human
G Del Monte-, M Ramialison, AAS Adam, B Wu, A Aharonov, G D'Uva, LM Bourke, ME Pitulescu, H Chen, JL de la Pomp, W Shou, RH Adams, SK Harten, E Tzahor, B Zhou, RP Harvey Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation Nature, 2018-05-09;0(0):. 2018-05-09 [PMID: 29743679] (Bioassay, Mouse)	Bioassay	Mouse
LC Schmitt, A Rau, O Seifert, J Honer, M Hutt, S Schmid, J Zantow, M Hust, S Dübel, MA Olayioye, RE Kontermann Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV MAbs, 2017-04-19;0(0):0. 2017-04-19 [PMID: 28421882] (Bioassay, Human)	Bioassay	Human
YC Xu, X Wang, Y Chen, SM Chen, XY Yang, YM Sun, MY Geng, J Ding, LH Meng Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer Theranostics, 2017-02-23;7(4):974-986. 2017-02-23 [PMID: 28382169] (Bioassay, Human)	Bioassay	Human
M Kawata, S Morikawa, S Shiosaka, H Tamura Ablation of neuropsin-neuregulin 1 signaling imbalances ErbB4 inhibitory networks and disrupts hippocampal gamma oscillation Transl Psychiatry, 2017-03-07;7(3):e1052. 2017-03-07 [PMID: 28267150] (Bioassay)	Bioassay
McElroy S, Castle S, Bernard J, Almohazey D, Hunter C, Bell B, Al Alam D, Wang L, Ford H, Frey M The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis. Am J Pathol, 2014-09-09;184(10):2768-78. 2014-09-09 [PMID: 25216938] (Bioassay, Mouse)	Bioassay	Mouse
Desai , Tushar J, Brownfield , Douglas, Krasnow , Mark A Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature, 2014-02-05;507(7491):190-4. 2014-02-05 [PMID: 24499815] (Bioassay, Mouse)	Bioassay	Mouse
Lee , Cleo Yi-, Lin , Yuan, Bratman , Scott V, Feng , Weiguo, Kuo , Angera H, Scheeren , Ferenc A, Engreitz , Jesse M, Varma , Sushama, West , Robert B, Diehn , Maximili Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. Cancer Res, 2013-10-31;74(1):341-52. 2013-10-31 [PMID: 24177178] (Bioassay, Human)	Bioassay	Human
Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, Belzil V, Dion P, Higasa K, Doi K, Ishiura H, Mitsui J, Date H, Ahsan B, Matsukawa T, Ichikawa Y, Moritoyo T, Ikoma M, Hashimoto T, Kimura F, Murayama S, Onodera O, Nishizawa M, Yoshida M, Atsuta N, Sobue G, Fifita J, Williams K, Blair I, Nicholson G, Gonzalez-Perez P, Brown R, Nomoto M, Elenius K, Rouleau G, Fujiyama A, Morishita S, Goto J, Tsuji S ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet, 2013-10-10;93(5):900-5. 2013-10-10 [PMID: 24119685] (Bioassay, Human)	Bioassay	Human
Gorbatenko A, Olesen C, Morup N, Thiel G, Kallunki T, Valen E, Pedersen S ErbB2 upregulates the Na+,HCO3(-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4. FASEB J, 2013-10-02;28(1):350-63. 2013-10-02 [PMID: 24088818] (Bioassay, Human)	Bioassay	Human
Ishibashi K, Fukumoto Y, Hasegawa H, Abe K, Kubota S, Aoyama K, Kubota S, Nakayama Y, Yamaguchi N Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src. J Cell Sci, 2012-12-10;126(0):625-37. 2012-12-10 [PMID: 23230144] (Bioassay, Human, Mouse, Primate - Chlorocebus aethiops (African Green Monkey))	Bioassay	Human, Mouse, Primate - Chlorocebus aethiops (African Green Monkey)
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human)	Bioassay	Human
Hickinson DM, Klinowska T, Speake G AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin. Cancer Res., 2010-02-09;16(4):1159-69. 2010-02-09 [PMID: 20145185] (Bioassay, Human)	Bioassay	Human
Show All 21 Publications. Collapse Publications.

Array 5898-NR

• Neuregulin-1/NRG1 Antibodies
• Neuregulin-1/NRG1 ELISA Kits
• Neuregulin-1/NRG1 Lysates
• Neuregulin-1/NRG1 Proteins and Enzymes